Articles tagged with Rheumatoid Arthritis
A Mayo Clinic study found a significant association between rheumatoid arthritis and chronic lung diseases, with cumulative incidence rates increasing over time. The study followed 603 patients with RA for up to 30 years, revealing higher rates of obstructive lung disease and diffuse parenchymal infiltrative lung disease.
Enbrel, a biologic treatment, demonstrates sustained improvements in rheumatoid arthritis symptoms over up to nine years. Patients showed significant reductions in joint pain, stiffness, and disability.
A population-based study of 393 patients with rheumatoid arthritis found that they aged at approximately 1.25 times the rate of people in the general population. This accelerated aging was consistent with increased mortality rates among RA patients, emphasizing the need for early diagnosis and intervention to address total health.
Repeat MabThera treatment improves physical and mental aspects of quality of life measures in RA patients, with significant improvements in disease symptoms and structure. The therapy also inhibits joint structural damage, providing evidence of radiographic progression inhibition.
Researchers at UCI identified natural compounds that block autoimmune T-cell activity, potentially developing new treatments for type-1 diabetes and rheumatoid arthritis. The study found the compounds suppressed autoimmune T-cell function without affecting other immune cells.
A new study by researchers at the University of Arizona found that turmeric extract can prevent experimental rheumatoid arthritis and reduce bone loss. The curcuminoid extract inhibited the activation of NF-KB, a protein that enhances production of inflammatory proteins, and blocked the pathway that affects bone resorption.
Researchers found evidence that nitric oxide signaling may be responsible for overproduction in RA patients. The study suggests a new perspective on the disease's cause and could offer insights into other autoimmune diseases.
Researchers found PLC-gamma-2 crucial for normal osteoclast development and function in mice with rheumatoid arthritis (RA). The protein also regulates B cell differentiation, suggesting a potential therapeutic target for controlling joint destruction and bone erosion.
A new study found that many primary care trusts in the UK are refusing to fund adequate treatment for rheumatoid arthritis (RA) patients, despite NICE approval. The study revealed a postcode lottery, where funding and access to effective treatments like anti-TNF therapy vary widely across the country.
The study found that male sex influences RA mechanisms, with higher production of anti-CCP antibodies in families with affected male members. Female patients also exhibit differences in disease expression and response to treatment.
A Stanford study finds that the cancer drug Gleevec, used to combat leukemia and gastrointestinal cancers, may also be effective in treating rheumatoid arthritis. The researchers tested Gleevec on mice with a condition similar to human rheumatoid arthritis and found it almost completely prevented disease development.
Researchers found that imatinib can block the development of disease in a mouse model of rheumatoid arthritis, providing hope for a new treatment. Additionally, studying adrenomedullin's effect on female mice revealed that reduced expression may severely decrease fertility. Meanwhile, a study on TNF-alpha discovered that it decreases e...
Researchers at Stanford University have found that Gleevec can block the development of disease in a mouse model of rheumatoid arthritis, providing hope for a new treatment. Imatinib inhibits the function of immune cells contributing to RA and also suppresses joint cell proliferation.
A study by UCSD researchers shows that the central nervous system can sense and modulate inflammation in joints, reducing symptoms of rheumatoid arthritis. Blocking key signaling enzymes in the CNS resulted in decreased joint inflammation and destruction.
A new study published in PLoS Medicine suggests that delivering rheumatoid arthritis drugs directly into the central nervous system improves treatment outcomes. Researchers found that blocking a protein called p38 with spinal cord administration reduced inflammation, arthritis, and joint destruction in arthritic rats.
Researchers investigated association between TNF blocker use and cancer risk in RA patients. They found no increased risk of lymphoma or tumors associated with anti-TNF therapy over methotrexate use. The study used a large sample of patients and found an overall difference in estimated cancer risk less than 5 percent.
Research found that smoking significantly increased the odds of developing rheumatoid arthritis in older Caucasian women without a genetic risk factor. The study, which included 115 postmenopausal women, revealed that tobacco smoke exposure doubled the risk of disease development.
Researchers found three genes over-expressed in rheumatoid arthritis that varied between identical twin pairs, suggesting environmental factors influence gene expression. The discovery provides insights into the variability of disease symptoms and response to treatment.
Researchers have uncovered three disease-relevant genes in synovial tissue from identical twins with RA, shedding light on the genetic components of this inflammatory disease. The study identifies laeverin, 11ß-HSD2, and Cyr61 as key enzymes linked to protein degradation, inflammation, and new blood vessel formation.
A study of 25 pregnant women with inflammatory arthritis found that changes in serum fetal DNA levels correlated with disease improvement during pregnancy, but not postpartum. The researchers observed a significant inverse correlation between arthritis activity and serum fetal DNA concentration throughout the study.
Research reveals rheumatoid arthritis significantly impacts patients' sexual activity, with fatigue and functional limitation being key predictors. The study highlights the need for increased attention to this often taboo topic in healthcare, emphasizing the importance of addressing sexual problems as part of general RA care.
The study found that HAQ responsiveness decreases with increasing RA duration, suggesting an irreversible disability component. This makes it challenging to detect functional improvement and distinguish it from placebo effects.
New research suggests that treatment with TNF inhibitors reduces cardiovascular events, including myocardial infarction and cerebrovascular accidents, in rheumatoid arthritis patients. However, a separate study found an increased risk of serious infections in patients treated with TNF inhibitors.
A large patient group observed for five years found that women with rheumatoid arthritis (RA) had a more aggressive disease course compared to men. Only 32% and 31% of women were in remission at 2 and 5 years, respectively, whereas 49% and 52% of men achieved remission during the same period.
A double-blind phase III study found tocilizumab improved signs and symptoms of active rheumatoid arthritis by 80.3% at 24 weeks, compared to 25.0% for methotrexate. The treatment was well-tolerated, with few adverse events reported.
Rituximab plus methotrexate treatment significantly inhibits joint structural damage, reducing bone erosions and joint space narrowing in patients. The study's findings offer new hope for those who do not respond to current treatments.
A study across 5 Norwegian departments found that anti-TNF treatments worked better in patients with PsA and AS compared to RA. The combination of anti-TNF and MTX was shown to improve adherence and outcomes in these groups, while monotherapy was more effective for RA patients.
The REFLEX study demonstrated that MabThera can inhibit structural joint damage in patients with an inadequate response to TNF inhibitors. Repeated treatment courses provided continued improvement of symptoms across all clinical measures, increasing remission rates and symptom improvement.
The study found that the PTPN22 gene risk variant is associated with increased articular damage progression in rheumatoid arthritis patients. The researchers also discovered a link between the T allele carrier status and the annual rate of radiographic damage progression.
The TEMPO extension trial found that adding Enbrel to methotrexate improved clinical remission rates, reduced disease activity, and enhanced quality of life among patients with rheumatoid arthritis. The study showed significant benefits in patients who had not achieved adequate response with methotrexate monotherapy.
Long-term data from a study showed that abatacept treatment significantly slowed the progression of structural damage in rheumatoid arthritis patients who had an inadequate response to methotrexate. The effect was seen at year 2 and continued into the second year, suggesting progressive improvement.
A recent study found that methotrexate can delay and prevent the progression of rheumatoid arthritis in patients. Patients who showed a positive anti-CCP test benefited the most from the treatment, indicating a lower risk of developing full-blown RA.
Researchers found that GM-CSF and TNF-alpha induce the phosphorylation of a serine residue on NADPH oxidase, priming it for action at sites of inflammation. This prime may be targeted with drugs to prevent exaggerated neutrophil responses in inflammatory conditions like rheumatoid arthritis.
A study of over 2000 blood samples found that individuals with unfavourable blood fat levels were more likely to develop rheumatoid arthritis. Total cholesterol and triglyceride levels were higher in those who developed the disease, indicating an increased risk of ischaemic heart disease.
The study found that ethnicity, quality of the doctor-patient relationship, disease activity, and trust in the US healthcare system are all associated with patients' trust in their doctors. Patient-centered communication was significantly linked to increased information sharing by patients.
A study of 295 children with JRA found that Medicaid recipients had higher disease activity, more pain, and lower physical function compared to those with private insurance. The reasons for these disparities are not yet clear, but may be linked to non-treatment-related factors such as poverty and adherence to treatment.
A study found that patients with rheumatoid arthritis treated with TNF-blocking antibodies are at a higher risk of developing cancer and serious infections. The drugs, which were previously thought to be safe, may interfere with the body's ability to fight off infection and cancer.
An international study found that low-dose rituximab can achieve remission in patients with moderate to severe rheumatoid arthritis symptoms. The treatment showed no correlation between steroid use and disease improvement, but was associated with mild adverse events.
Adult stem cells can make new tendon tissue and repair damaged tendons in rats. The study demonstrates potential for using this technology to treat musculoskeletal injuries and degenerative diseases.
Researchers developed RGD peptide liposomes to deliver dexamethasone phosphate directly to VECs at sites of inflammation, reducing arthritis severity and disease progression. The study demonstrates the potential of targeted liposomal therapy for treating rheumatoid arthritis.
Liposome technology has been shown to improve tissue delivery of therapeutic compounds, achieving effects equivalent to 10-fold higher doses. Specific targeting of liposomes to inflamed cells in the synovium has also been successfully demonstrated, reducing synovial inflammation without conventional side effects.
A Mayo Clinic study found that patients with rheumatoid arthritis have preserved hearing and are no more susceptible to hearing loss than those without the disease. However, rheumatoid arthritis patients were more likely to perceive they had hearing problems due to their disability level.
Researchers found a substantial link between severe rheumatoid arthritis and increased risk of lymphoma. Patients with high RA activity experienced a 70-fold increase in lymphoma risk, while those with low activity had an 8-fold increase.
A study of 79 patients found that renewed methotrexate treatment was effective in 53.2% of patients who had previously failed the drug. Lower initial doses were more likely to be successful than higher doses.
Researchers found patients with rheumatoid arthritis have a three-fold increase in carotid artery atherosclerosis compared to those without RA. Statins and b-blockers may also affect coronary heart disease severity, while hospital volume doesn't correlate with pneumonia care quality.
Researchers find that histamine contributes to joint blood vessel leakage in rheumatoid arthritis, potentially leading to more effective treatments. The discovery may also apply to other autoimmune conditions and infectious diseases.
Researchers found that statins, such as fluvastatin, can induce apoptosis in RA synovial cells through the inhibition of protein geranygeranylation. This suggests that statins may be ideal therapeutic agents for treating rheumatoid arthritis. Further clinical trials are proposed to confirm these findings.
Researchers found a strong link between smoking, HLA-DR SE genes, and anticitrulline antibodies in early rheumatoid arthritis patients. Smoking significantly raises RA risk for individuals testing positive for these antibodies, regardless of SE gene status.
A two-year study of patients with early, aggressive RA demonstrates the superiority of anti-TNF plus DMARD therapy over either treatment alone. Nearly half of participants in the combined therapy group achieved major clinical remission after 2 years.
Research confirms that individuals with a specific PTPN22 polymorphism are more likely to develop rheumatoid arthritis, with anti-CCP antibodies also playing a key role. The combination of these factors strongly predicts the onset of RA with a specificity of 100% for the disease.
Long-term Phase 3 data from ACT 1 and ACT 2 trials demonstrate REMICADE's efficacy in achieving clinical response, clinical remission, and mucosal healing in UC patients. Approximately two-thirds of patients treated with REMICADE achieved the primary endpoint of clinical response.
A study found that chemical modification of Type II Collagen creates a self-antigen, leading to immune system activation in rheumatoid arthritis patients. The modification of this protein contributes significantly to the disease's progression.
A phase III study shows Actemra significantly reduces radiographic joint destruction and disease activity scores in patients with early aggressive rheumatoid arthritis. The treatment was generally well-tolerated, with a low incidence of adverse events.
Patients with active psoriatic arthritis treated with REMICADE experienced a high degree of sustained clinical improvement in arthritis, including significant reduction in structural damage. The treatment also showed sustained improvement in functional status and quality of life, as measured by the Short Form 36 questionnaire.
MabThera demonstrates significant improvements in symptom parameters, including tender and swollen joint counts and fatigue, with higher response rates compared to methotrexate alone. The treatment was well-tolerated, with consistent safety profiles across the six-month analysis.
Researchers have found that women with lupus are at high risk of heart disease due to the presence of pro-inflammatory HDL in their blood. The discovery may lead to an effective test to identify patients at increased risk and prevent cardiovascular morbidity and mortality.
Golimumab, a fully-human anti-TNF-alpha monoclonal antibody, achieves primary endpoint and shows significant improvement in signs and symptoms of moderately to severely active rheumatoid arthritis. Patients receiving golimumab plus MTX achieved higher ACR response rates compared to placebo.
The TEMPO study demonstrated that over three-quarters of patients treated with Enbrel plus methotrexate experienced no progression of joint damage. Additionally, patients treated with this combination therapy showed a significant improvement in physical function compared to those receiving either treatment alone.
A Stanford study finds that women with rheumatoid arthritis and lupus are at higher risk for adverse outcomes during pregnancy, including hypertension, premature delivery, and cesarean sections. The research highlights the need for better understanding of these autoimmune conditions in pregnant women.
Researchers have identified a specific FCGR3A-FCGR3B haplotype associated with an increased risk of developing rheumatoid arthritis. Homozygous individuals with this haplotype are three times more likely to develop RA, and those with the shared epitope protein sequence have a 10 times higher risk.